Medivation has FDA Backing







Wedbush Securities analyst David Nierengarten predicts urologists will prefer the rival therapies because they utilize a familiar approach — hormone manipulation — and are simpler to use. ""I see a diminishing role for Provenge going forward," he said in a telephone interview.
 
























The Medivation approval will have some effect on Provenge, but the bigger concern is if Zytiga gets approved in the prechemotherapy setting.

Zytiga is secondary to Medivation approval. Medivation approval was the end of Dendreon. Not the end of Provenge, but the end of Dendreon. Dendreon BoD got their wish...
 












Yes the Medivation dug approval is good news for Dendreon. Medivation's drug does not have to be taken with streroids like Zytiga. As a result of the steroid, there may need to be a treatment time spacing with a provenge/zytiga combo treatment (Dendreon is currently testing this combo in a clinical trial). The Medivation drug can currently be taken in combination with provenge. As is the case with all oncology drugs, this will encourage combined or sequential treatment with both provenge and the Medivation drug.
 






Yes the Medivation dug approval is good news for Dendreon. Medivation's drug does not have to be taken with streroids like Zytiga. As a result of the steroid, there may need to be a treatment time spacing with a provenge/zytiga combo treatment (Dendreon is currently testing this combo in a clinical trial). The Medivation drug can currently be taken in combination with provenge. As is the case with all oncology drugs, this will encourage combined or sequential treatment with both provenge and the Medivation drug.

This post may be 100% correct. The share value has plunged since this event but again this poster may be correct. He's a good source of info. Please ignore the fact that the value has plunged from 57 to 3 while he has been pumping it.